Robertson R P
Diabetes Center, University of Minnesota Medical School, Minneapolis.
Diabetes. 1991 Sep;40(9):1085-9. doi: 10.2337/diab.40.9.1085.
Pancreas transplantation, when successful, is a reproducibly effective method to normalize glycemia without the use of exogenous insulin treatment in patients with diabetes mellitus. Success rates for combined pancreas and kidney transplantation are approximately 70%, and patient survival rates are approximately 90% 1 yr postoperatively. Metabolic benefits of this procedure include normalization of levels of fasting plasma glucose and HbA1C. Glucose-induced insulin secretion and intravenous glucose tolerance are normalized. Improvements are also observed in glucose recovery after insulin-induced hypoglycemia and in glucagon secretion during hypoglycemia. Pancreas transplantation is also associated with normalization of kidney structure and both motor and sensory nerve function. However, no benefits have been observed with regard to pancreatic polypeptide secretion, kidney function, and the retinal pathology of diabetes mellitus. Pancreas transplantation has reached a point in its history where the operative technique and its ancillary medical therapy have been optimized. Improvement in the rates of success, morbidity, and mortality will probably depend on improvement in immunosuppressive drugs and the physical condition of the recipients themselves. The time is at hand when we need to carefully consider whether it is ethical and advisable to make pancreas transplantation available to individuals who have fewer chronic complications of diabetes mellitus. Future studies of pancreas transplantation must incorporate more rigid experimental controls than have been used in the past to better assess the relative merits of this procedure.
胰腺移植若获成功,对于糖尿病患者而言,是一种能在不使用外源性胰岛素治疗的情况下使血糖正常化的可重复有效的方法。胰腺联合肾脏移植的成功率约为70%,术后1年患者生存率约为90%。该手术的代谢益处包括空腹血糖水平和糖化血红蛋白A1C水平正常化。葡萄糖诱导的胰岛素分泌和静脉葡萄糖耐量恢复正常。胰岛素诱导低血糖后的血糖恢复以及低血糖期间的胰高血糖素分泌也有所改善。胰腺移植还与肾脏结构以及运动和感觉神经功能的正常化相关。然而,在胰腺多肽分泌、肾功能和糖尿病视网膜病变方面未观察到益处。胰腺移植在其发展历程中已达到这样一个阶段,即手术技术及其辅助药物治疗已得到优化。成功率、发病率和死亡率的改善可能取决于免疫抑制药物的改进以及受者自身的身体状况。现在是我们需要认真考虑将胰腺移植提供给糖尿病慢性并发症较少的个体是否符合伦理道德且明智的时候了。未来的胰腺移植研究必须纳入比过去更严格的实验对照,以便更好地评估该手术的相对优势。